Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-07-10
2007-07-10
Lankford, L Blaine (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000, C424S193100
Reexamination Certificate
active
10106804
ABSTRACT:
Heparin-binding regions of several proteins, such as neural cell adhesion molecule, fibronectin, laminin, midkine, and anti-thrombin III have been shown to promote neurite extension on two-dimensional surfaces. The effect of heparin-binding peptides on neurite extension through three-dimensional matrices was investigated by culturing embryonic chick dorsal root ganglia (DRG) within fibrin gels containing chemically attached heparin-binding peptide (HBP). The length of neurites within fibrin gels containing cross-linked HBP was increased by more than 70% over extension through fibrin gels containing no peptide. The HBP sequence of antithrombin III was incorporated into the fibrin gel as the C-terminal domain of a bidomian, chimeric peptide; the N-terminal second domain of this peptide contained the ∀2-plasmin inhibitor substrate for Factor XIIIa. Factor XIIIa, a transglutaminase, was used to chemically attach the HBP-containing chimeric peptide to the fibrin gels during polymerization. The amount of HBP cross-linked into the fibrin gels was determined, after degradation by plasmin using gel permeation chromatography, to be approximately 8 moles of peptide per mole fibrinogen. A peptide (HBP), where the cross-linking glutamine was replaced with glycine, showed no increase in extension in comparison with fibrin gels. The additional of heparin to the gel percursors resulted in no increase in neurite extension in comparison with fibrin gels. HBPs promote neurite extension by binding to cell surface proteoglycans on the DRG.
REFERENCES:
patent: 4613665 (1986-09-01), Larm
patent: 4810784 (1989-03-01), Larm
patent: 4894436 (1990-01-01), Auerswald et al.
patent: 5032573 (1991-07-01), Auerswald et al.
patent: 5100668 (1992-03-01), Edelman et al.
patent: 5171670 (1992-12-01), Kronenberg et al.
patent: 5202247 (1993-04-01), Kilburn et al.
patent: 5258302 (1993-11-01), Vedvick et al.
patent: 5428014 (1995-06-01), Labroo et al.
patent: 5549904 (1996-08-01), Juergensen et al.
patent: 5582862 (1996-12-01), Reed
patent: 5591603 (1997-01-01), Bjørn et al.
patent: 5641670 (1997-06-01), Treco et al.
patent: 5651982 (1997-07-01), Marx
patent: 5693341 (1997-12-01), Schroeder et al.
patent: 5773577 (1998-06-01), Capello
patent: 5840837 (1998-11-01), Krstenansky et al.
patent: 6054122 (2000-04-01), MacPhee et al.
patent: 6117425 (2000-09-01), MacPhee et al.
patent: 6197325 (2001-03-01), MacPhee et al.
patent: 6331422 (2001-12-01), Hubbell et al.
patent: 6559119 (2003-05-01), Burgess et al.
patent: 0 732 105 (1996-09-01), None
patent: 0 838 219 (1998-04-01), None
patent: WO 89/00051 (1989-01-01), None
patent: WO 90/05177 (1990-05-01), None
patent: WO 92/02620 (1992-02-01), None
patent: WO 92/09301 (1992-06-01), None
patent: WO 92/22312 (1992-12-01), None
patent: WO 94/20133 (1994-09-01), None
patent: WO 95/05396 (1995-02-01), None
patent: WO 95/23611 (1995-09-01), None
patent: WO 96/16983 (1996-06-01), None
patent: WO 96/17633 (1996-06-01), None
patent: WO 98/12228 (1998-03-01), None
patent: WO 99/08717 (1999-02-01), None
patent: WO 99/21588 (1999-05-01), None
Webb. Enzyme Nomenclature. 1984. p. 177.
Besson, et al. “Synthetic peptide substrates for a conductimetric assay ofPseudomonas aeruginosaelastase,”Analytical Biochemistry237(0232):216-223 (1996).
Blaschuk, et al., “Identification of a cadherin cell adhesion recognition sequence,”Dev. Biol139(1):227-229 (1990).
Borrajo, et al., “Derivatized Cyclodextrins as peptidometics: Influence on Neurite Growth,”Bioorganic and Medicinal Chemistry Letters7:1185-90 (1997).
Chuah, et al., “Differentiation and survival of rat olfactory epithlial neurons in dissociated cell culture,”Dev Brain Res60(2):123-132 (1991).
Coombs, et al. “Directing sequence-specific proteolysis to new targets. The influence of loop size and target sequence on selective proteolysis by tissue-type plasminogen activator and urokinase-type plasminogen activator,”J. Biol. Chem.273(8):4323-8 (1998).
Dimilla, et al., “Mathematical model for the effects of adhesion and mechanics on cell migration speed,”Biophys. J.60(1):15-37 (1991).
Dinbergs, et al., “Cellular response to transforming growth factor-beta1 and basic fibroblast growth factor depends on release kinetics and extracellular matrix interactions,”J. Biol. Chem. 271(47):29822-9 (1996).
Edelman, et al., “Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries,”J. Clin. Invest.89(2):465-73 (1992).
Edelman, et al., “Controlled and modulated release of basic fibroblast growth factor,”Biomaterials. 12(7):619-26 (1991).
Edelman, et al., “Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition,”Proc. Natl. Acad. Sci. U. S. A. 90(4):1513-7 (1993).
Edgar, et al., “The heparin-binding domain of laminin is responsible for its effects on neurite outgrowth and neuronal survival,”EMBO J. 3(7):1463-8 (1984).
Fowlkes, et al., “Characterization of gylcosaminoglycan-binding domains present in insulin-like growth factor-binding protein-3,”J Biological Chemistry271(25):14676-9 (1996).
Götz, et al., “Neurotrophin-6 is a new member of the nerve growth factor family,”Nature372(6503):266-9 (1994).
Harada, et al., “Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts,”J. Clin. Invest. 94(2):623-30 (1994).
Hata, et al., “Binding of lipoprotein lipase to heparin. Identification of five critical residues in two distinct segments of the amino-terminal domain,”J. Biol. Chem. 268(12):8447-57 (1993).
Haugen, et al, “Central and peripheral neurite outgrowth differs in preference for heparin-binding versus integrin-binding sequences,”J. Neurosci. 12(6):2034-42 (1992).
Herbert, et al., “Effects of fibinolysis on neurite growth from dorsal root ganglia cultured in two- and three-dimensional fibrin gels,”J. Comp. Neurol. 365(3):380-91 (1996).
Herbert, et al., “Effects of fibrin micromorphology on neurite growth from dorsal root ganglia cultured in three-dimensional fibrin gels,”J. Biomed. Mater. Res. 40(4):551-9 (1998).
Kallapur, et al., “The neural cell adhesion molecule (NCAM) heparin binding domain binds to cell surface heparan sulfate proteoglycans,”J. Neurosci. Res. 33(4):538-48 (1992).
Kaneda, et al., “Midkine, a heparin-binding growth/differentiation factor, exhibits nerve cell adhesion and guidance activity for neurite outgrowth in vitro,”J. Biochem. 119(6):1150-6 (1996).
Kiguchi, et al., “Altered expression of epidermal growth factor receptor ligands in tumor promoter-treated mouse epidermis and in primary mouse skin tumors induced by an initiation-promotion protocol,”Mol. Carcinog. 22(2):73-83 (1998).
Kinosaki, et al., “Identification of heparin-binding stretches of a naturally occurring deleted variant of hepatocyte growth factor (dHGF),”Biochim. Biophys. Acta. 1384(1):93-102 (1998).
Kleinman, et al., “The laminins: a family of basement membrane glycoproteins important in cell differentiation and tumor metastases,”Vitam. Horm.47:161-86 (1993).
Kleinman, et al.,Vitamins and Hormones47:10-93 (1993).
Lopez, et al., “Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: a comparison of anaiographic, echocardiographic and coronary flow parameters,”J. Pharmacol. Exp. Ther. 282(1):385-90 (1997).
Lopez, et al., “Local perivascular administration of basic fibroblast growth factor: drug delivery and toxicological evaluation,”Drug Metab. Dispos. 24(8):922-4 (1996).
Martin & Timpl, “Laminin and other basement membrane components,”Annu. Rev. Cell. Biol. 3:57-85 (1987).
Massia, et al., “An RGD spacing of 440 nm is sufficient for integrin alpha V beta 3-mediated fibroblast spreading
Hubbell Jeffrey A.
Sakiyama Shelly E.
Schense Jason C.
Eidgenossische Technische Hochschule Zurich
Lankford L Blaine
Pabst Patent Group LLP
Universitat Zurich
LandOfFree
Enzyme-mediated modification of fibrin for tissue... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enzyme-mediated modification of fibrin for tissue..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enzyme-mediated modification of fibrin for tissue... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3819323